Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats
Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.00959-17
Full Text
Open PDFAbstract
Available in full text
Date
August 14, 2017
Authors
Publisher
American Society for Microbiology